• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Captisol® improves the solubility of Anti-Tubercular drugs

    Thumbnail
    View/Open
    24859.pdf (28.91Kb)
    Author(s)
    Haywood, Alison
    Grant, GD
    Glass, BD
    Griffith University Author(s)
    Haywood, Alison
    Grant, Gary D.
    Year published
    2003
    Metadata
    Show full item record
    Abstract
    Purpose. There are global concerns on the quality of anti-tuberculosis (TB) fixed dose combination (FDC) products, a matter receiving attention from the World Heath Organisation (WHO). The bioavailability of rifampicin (RIF) has been found to reduce when in combination with other anti-tubercular agents due to the formation of insoluble complexes. The availability of a combination liquid dosage form for the treatment of TB in children is limited by both solubility and stability issues. This study was undertaken to investigate the effect of selected cyclodextrins (CDs) such as Captisola sulfobutylether-?-CD) and 2-hydroxypropyl-?-CD ...
    View more >
    Purpose. There are global concerns on the quality of anti-tuberculosis (TB) fixed dose combination (FDC) products, a matter receiving attention from the World Heath Organisation (WHO). The bioavailability of rifampicin (RIF) has been found to reduce when in combination with other anti-tubercular agents due to the formation of insoluble complexes. The availability of a combination liquid dosage form for the treatment of TB in children is limited by both solubility and stability issues. This study was undertaken to investigate the effect of selected cyclodextrins (CDs) such as Captisola sulfobutylether-?-CD) and 2-hydroxypropyl-?-CD (HPB) on the solubility of RIF alone and in combination with the other anti-tuberculosis agents, namely; isoniazid (INH) and pyrazinamide (PZA). Methods. A stability-indicating HPLC method was developed and validated for the quantitation of these three drugs in combination. Sample preparation involved the addition of excess drug candidate, alone and in combination, to aqueous cyclodextrin solutions of varying concentrations. The resulting suspensions were agitated at room temperature (25 + 0.5ꃩ for 12 hours and the supernatant analysed for the drug candidate. Results. The solubility of RIF and PZA was enhanced in the presence of Captisol0.092 M) from 1.236 to 7.700 mg/ml and 20.331 to 23.460 mg/ml respectively while for HPB (0.141 M) increases in solubility of RIF and PZA from 1.611 to 4.757 mg/ml and 18.116 to 23.959 mg/ml were achieved. These results demonstrate the superior solubilising ability of Captisolver that of HPB especially for RIF whose inclusion in liquid dosage forms in adequate concentrations has proved to be problematic. Conclusions. Captisolas enhanced the solubility of RIF and PZA, providing new formulation opportunities for FDC products for the treatment of TB in the paediatric population.
    View less >
    Conference Title
    Australasian Pharmaceutical Science Association (APSA)
    Publisher URI
    http://www.apsa-online.org/
    Copyright Statement
    © 2003 APSA. This is the author-manuscript version of this paper.
    Publication URI
    http://hdl.handle.net/10072/10075
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander